 |
      
|
|
|
|
|
|||||
|
|
May 20, 2004
Neurochem to present at Banc of America Securities' Health Care Conference and at
UBS 2004 Global Specialty Pharmaceuticals Conference. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's pipeline of proprietary, disease-modifying, oral products
addresses critical, unmet medical needs. Fibrillex™, designated as an orphan drug and as a
Fast Track Product candidate, is in a Phase II/III clinical trial for the treatment of Amyloid A
Amyloidosis. Alzhemed™ and Cerebril™, for the treatment of Alzheimer's Disease and for
the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, respectively, have both
completed a Phase II clinical trial. For additional information on Neurochem, please visit our
website at: (www.neurochem.com).
Certain statements contained in this news release, other than statements of fact that are
independently verifiable at the date hereof, may constitute forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control.
Such risks include but are not limited to: the impact of general economic conditions, general
conditions in the pharmaceutical industry, changes in the regulatory environment in the
jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation as well as other risks included
in public filings of Neurochem. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements. The reader should not place
undue reliance on the forward-looking statements included in this news release. These statements
speak only as of the date made and Neurochem is under no obligation and disavows any intention to
update or revise such statements as a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
